Does P2Y12 inhibitor monotherapy with ticagrelor reduce mortality and bleeding risk compared to standard DAPT in patients undergoing percutaneous coronary intervention?
In patients undergoing PCI, P2Y12 monotherapy with ticagrelor may reduce mortality and bleeding risk compared to standard DAPT without increasing ischemic events.
In comparison to standard DAPT, P2Y12 inhibitor monotherapy with ticagrelor may lead to a reduced mortality. The clinical benefits are driven by a reduction of bleeding risk without ischemic risk trade-off.
Casula et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: